The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …
However, in some countries, such as Netherlands, high discounts reported for the originator …
Key issues surrounding appropriate antibiotic use for prevention of surgical site infections in low-and middle-income countries: a narrative review and the implications
Background There is a concern with the growing use of antimicrobials across countries
increasing antimicrobial resistance (AMR) rates. A key area within hospitals is their use for …
increasing antimicrobial resistance (AMR) rates. A key area within hospitals is their use for …
Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure
S Vogler, P Schneider, M Zuba, R Busse… - Frontiers in …, 2021 - frontiersin.org
Introduction: Biosimilar medicines are considered promising alternatives to new biologicals
with high price tags. The extent of savings resulting from biosimilar use depends on their …
with high price tags. The extent of savings resulting from biosimilar use depends on their …
A narrative review of antibiotic prescribing practices in primary care settings in South Africa and potential ways forward to reduce antimicrobial resistance
A Chigome, N Ramdas, P Skosana, A Cook… - Antibiotics, 2023 - mdpi.com
There are concerns with the current prescribing of antibiotics in both the private and public
primary care settings in South Africa. These concerns need to be addressed going forward …
primary care settings in South Africa. These concerns need to be addressed going forward …
Evidence-based public policy making for medicines across countries: findings and implications for the future
Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …
The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and …
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of
associated complications has appreciably increased global expenditure in recent years. The …
associated complications has appreciably increased global expenditure in recent years. The …
Association of generic competition with price decreases in physician-administered drugs and estimated price decreases for biosimilar competition
SR Dickson, T Kent - JAMA network open, 2021 - jamanetwork.com
Importance Price decreases of biologic and biosimilar products in Medicare Part B have
been minimal, even with biosimilar competition. Medicare reimburses clinicians for biologics …
been minimal, even with biosimilar competition. Medicare reimburses clinicians for biologics …
Initiatives and reforms across Scotland in recent years to improve prescribing; findings and global implications of drug prescriptions
S MacBride-Stewart, S McTaggart… - … Journal of Clinical …, 2021 - pureportal.strath.ac.uk
Objective: Global expenditure on medicines is increasing driven by a number of factors.
These include the launch of new premium-priced medicines for complex diseases including …
These include the launch of new premium-priced medicines for complex diseases including …
Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades
M Büssgen, T Stargardt - BMC Health Services Research, 2022 - Springer
Background The timing of the launch of a new drug is an important factor that determines
access for patients. We evaluated patient access to pharmaceuticals in 30 European …
access for patients. We evaluated patient access to pharmaceuticals in 30 European …
Is the availability of biosimilar adalimumab associated with budget savings? A difference-in-difference analysis of 14 countries
Objective The aim was to assess the influence of the presence of biosimilar adalimumab on
adalimumab budget savings in 14 high-and upper-middle-income countries. Methods This …
adalimumab budget savings in 14 high-and upper-middle-income countries. Methods This …